Ipamorelin
NNC 26-0161 · GH secretagogue
A relatively selective GH secretagogue investigated in limited human pharmacology and postoperative settings.
Mechanism
Ghrelin receptor agonist / growth hormone secretagogue
Protocol studied in research
Study design shown in plain language. This is not a personal dosing recommendation.
Adults following bowel resection
Community-Reported Research Schedules
Descriptive community patterns are separated from clearly labeled trial-derived reference rows. Neither is personal dosing guidance.
The reference separates assessment, titration, standard, extended and off-cycle phases.
| Research context or phase | Amount per administration | Schedule total | Frequency | Timing | Administration | Evidence level |
|---|---|---|---|---|---|---|
| Assessment · Week 1 | 100 mcg | 100 mcg/day | Once daily | Bedtime, fasted | Subcutaneous | Community-reported |
| Titration · Weeks 2–3 | 100–200 mcg | 200 mcg/day | Once daily or divided | Bedtime or morning fasted plus bedtime | Subcutaneous | Community-reported |
| Standard · Weeks 4–8 | 100–300 mcg | 200–300 mcg/day | Once or twice daily | Morning fasted and/or bedtime | Subcutaneous | Community-reported |
| Extended · Weeks 9–12 | 100–300 mcg | 200–300 mcg/day | Once or twice daily | Continue the established timing pattern | Subcutaneous | Community-reported |
| Off-cycle · 4 weeks | 0 mcg | 0 mcg/day | No administrations | Reported resting period | Not applicable | Community-reported |
Important: Repetition in online communities does not establish product identity, safety, effectiveness, or an appropriate exposure. Route-specific schedules, half-life estimates and reported cycle lengths are shown for comparison only.
Example Reconstitution Protocol
A hypothetical concentration calculation for literacy and review—not preparation, administration, or dosing instructions.
Important: Vial strength, diluent identity, compatibility, sterility, stability and beyond-use time are product-specific. Never infer them from this arithmetic example. Use manufacturer, pharmacy, study, or licensed-clinician instructions for an actual preparation.
Cycle & Supplies Planning
Phase-by-phase cycle math showing how long a vial lasts and the estimated supplies required.
Cycle Structure
| Phase | Amount | Frequency | Weekly total |
|---|---|---|---|
| Selected planning schedule | 100 mcg | Once daily | 0.7 mg/week |
Peptide Vials
| Cycle | Total compound | Vials needed | How long one vial lasts |
|---|---|---|---|
| 4 weeks | 2.8 mg | 1 × 10 mg | 100 administrations |
| 8 weeks | 5.6 mg | 1 × 10 mg | 100 administrations |
| 12 weeks | 8.4 mg | 1 × 10 mg | 100 administrations |
Bacteriostatic Water
| Cycle | Total water used | 10 mL bottles needed |
|---|---|---|
| 4 weeks | 3 mL | 1 × 10 mL |
| 8 weeks | 3 mL | 1 × 10 mL |
| 12 weeks | 3 mL | 1 × 10 mL |
Insulin Syringes (U-100)
| Cycle | Administrations | Syringes needed |
|---|---|---|
| 4 weeks | 28 | 28 |
| 8 weeks | 56 | 56 |
| 12 weeks | 84 | 84 |
Ranges reflect the low and high ends of the displayed community schedule. Vials and 10 mL water bottles are rounded up; one new U-100 syringe is counted per subcutaneous administration.
Planning boundary: These are arithmetic examples based on the displayed research schedule—not personal dosing or purchasing instructions. Confirm product format, compatibility, route, sterility, storage, and discard timing independently. U-100 units measure liquid volume, not potency.
Safety signal
Intravenous postoperative research does not establish chronic or subcutaneous use.
Reported doses describe either a specific study or an unverified community pattern. Neither is personal medical guidance.